Duron F
Service d'Endocrinologie, Hôpital Saint-Antoine, Paris, France.
Biomed Pharmacother. 1995;49(6):278-82. doi: 10.1016/0753-3322(96)82643-6.
Long term complications are the first causes of mortality and morbidity in diabetic patients. In Europe, many diabetologists speculated for a long time that a tight blood glucose control was the best way to avoid these complications, but without any complete evidence. In 1993, the results of the Diabetes Control and Complications Trial (DCCT), the first controlled, randomized, long term trial designed to study the link between metabolic control and complications in a large cohort of patients, has confirmed this hypothesis: in insulin-dependent diabetes mellitus, intensive insulin-therapy, as compared with conventional therapy, significantly reduces the risk of developing microvascular and neuropathic complications. Nevertheless, in some patients, the risk of hypoglycemia may outweight the benefit of intensive insulin therapy, and the results of the DCCT raises some questions about indications, the risk/benefit ratio and the cost/benefit ratio of intensive treatment.
长期并发症是糖尿病患者死亡和发病的首要原因。在欧洲,许多糖尿病专家长期以来一直推测,严格控制血糖是避免这些并发症的最佳方法,但没有任何确凿证据。1993年,糖尿病控制与并发症试验(DCCT)的结果证实了这一假设。DCCT是首个旨在研究一大群患者代谢控制与并发症之间联系的对照、随机、长期试验:在胰岛素依赖型糖尿病中,与传统治疗相比,强化胰岛素治疗显著降低了发生微血管和神经病变并发症的风险。然而,在一些患者中,低血糖风险可能超过强化胰岛素治疗的益处,并且DCCT的结果引发了一些关于强化治疗的适应症、风险/效益比和成本/效益比的问题。